Company Overview - Société BIC has a total of 41,621,162 issued shares as of June 30, 2025, which corresponds to 58,342,007 voting rights [2] - The company is a global leader in stationery, lighters, and shavers, with a presence in over 160 countries and a workforce of more than 13,000 employees [4] - BIC is recognized for its commitment to sustainability and education, and its products include well-known brands such as BIC® 4-Color™, BodyMark®, and Tipp-Ex® [4] Voting Rights and Shares - As of June 30, 2025, the number of voting rights excluding shares without voting rights is 57,941,174 [2] - The disclosure complies with Article L 233-8-II of the French "Code de Commerce" and Article 223-16 of the General Regulations of the French "Autorité des Marchés Financiers" [2] Upcoming Financial Events - The company is scheduled to release its First Half 2025 Results on July 30, 2025 [3] - The Third Quarter 2025 Net Sales will be announced on October 28, 2025 [3]

Core Insights - Société BIC has reported on its liquidity contract with Natixis ODDO BHF, detailing the resources on the liquidity account as of June 30, 2025 [2] - The report includes transaction volumes and trading activities from January 1 to June 30, 2025, in compliance with AMF Decision N°2021-01 [2] Group 1: Liquidity Contract Details - As of June 30, 2025, the liquidity account showed a total of 29,334 shares valued at €1,620,386.11 and 13,169 shares valued at €2,390,514.77 [5] - The total traded volume during the specified period included 260,495 shares purchased for €15,469,086.44 and 244,116 shares sold for €14,506,450.14 [5] - The report confirms that 2,008 purchases and 1,974 sales were executed during the period [5] Group 2: Company Overview - BIC is a global leader in stationery, lighters, and shavers, with a commitment to delivering high-quality and affordable products for 80 years [3] - The company operates in over 160 countries and employs more than 13,000 team members worldwide [3] - BIC's product portfolio includes well-known brands such as BIC® 4-Color™, BodyMark®, and Tipp-Ex®, and the company is listed on Euronext Paris [3]

Group 1 - As of May 31, 2025, Société BIC has a total of 41,621,162 issued shares, which represent 58,877,719 voting rights [2] - The number of voting rights excluding shares without voting rights is 58,480,587 [2] - BIC is a global leader in stationery, lighters, and shavers, with a presence in over 160 countries and a workforce of over 13,000 employees [4] Group 2 - BIC's product portfolio includes well-known brands such as BIC® 4-Color™, BodyMark®, and Tipp-Ex®, among others [4] - The company is listed on Euronext Paris and is included in the SBF120 and CAC Mid 60 indexes [4] - BIC is recognized for its commitments to sustainability and education [4]

Disclosure Of Trading In Own SharesFor May 2025 Clichy, France – June 05, 2025 In compliance with general regulation on share buy-backs, Société BIC declares below the transactions made on its own shares for May 2025: No transactions for May 2025. Contacts Brice ParisVP Investor Relations +33 6 42 87 54 73brice.paris@bicworld.com Investor Relationsinvestors.info@bicworld.com Bethridge ToovellVP Global Communications+1 917 821 4249bethridge.toovell@bicworld.com Isabelle de Segonzac Image 7, Press Rel ...

Publication in accordance with recommendation 26-1 of the AFEP-MEDEF Code of Corporate Governance for listed companies and in application of article L.22-10-13 of the French Commercial Code Change to the remuneration of the Chair of the Board of Directors Clichy, France – May 23, 2025 – In its meeting of May 20, 2025, under the chairmanship of Edouard Bich, the Board of Directors of Société BIC, upon the recommendation of the Remuneration Committee, decided the following: REMUNERATION FOR THE FISCAL YEAR ...

Combined Shareholders’ Meeting and Board of Directors of Société BIC of May 20th, 2025 Nomination of Edouard Bich as Director and Non-Executive Chair of the Board Renewal of Gonzalve Bich as Director and Chief Executive Officer Nomination of Esther Gaide as Lead Independent Director, Chair of the Audit Committee and member of the Remuneration CommitteeDistribution of ordinary dividend of 3,08 euros per share Clichy, France, May 20th, 2025 – The Combined Shareholders’ Meeting of Société BIC was held on Tu ...

Company Overview - As of March 31, 2025, the total number of issued shares of SOCIÉTÉ BIC is 41,621,162 shares [2] - BIC is a global leader in stationery, lighters, and shavers, with a presence in over 160 countries and a workforce of over 13,000 team members [2] - BIC's product portfolio includes well-known brands such as BIC® 4-Color™, BodyMark®, Cello®, Cristal®, and many others [2] Voting Rights - The total number of voting rights as of March 31, 2025, is 59,778,576 [5] - Excluding shares without voting rights, the number of voting rights is 59,483,209 [5] Upcoming Events - First Quarter 2025 Net Sales will be reported on April 23, 2025 [4] - The Annual General Meeting is scheduled for May 20, 2025 [4] - First Half 2025 Results will be announced on July 30, 2025 [4] - Third Quarter 2025 Net Sales will be reported on October 28, 2025 [4]

Company Overview - Société BIC has a total of 41,621,162 issued shares as of April 30, 2025, which corresponds to 59,669,051 voting rights [2] - The company is a global leader in stationery, lighters, and shavers, with a presence in over 160 countries and a workforce of over 13,000 employees [4] - BIC is recognized for its commitment to sustainability and education, and its products include well-known brands such as BIC® 4-Color™, BodyMark®, and Cristal® [4] Voting Rights and Share Capital - As of April 30, 2025, the number of voting rights excluding shares without voting rights is 59,273,677 [2] - The disclosure complies with Article L 233-8-II of the French "Code de Commerce" and Article 223-16 of the General Regulations of the French "Autorité des Marchés Financiers" [2] Upcoming Events - The Annual General Meeting is scheduled for May 20, 2025 [3] - The First Half 2025 Results will be announced on July 30, 2025 [3] - The Third Quarter 2025 Net Sales will be reported on October 28, 2025 [3]

Summary of Key Points Core Viewpoint - Société BIC has disclosed its share buy-back transactions for April 2025, indicating a strategic move to enhance shareholder value through repurchasing its own shares. Group 1: Share Buy-Back Transactions - In April 2025, BIC repurchased a total of 97,649 shares at an average weighted price of €59.7264, amounting to a total expenditure of €5,832,223.96 [2]. - The transactions included multiple purchases on different dates, with the largest single transaction occurring on April 3, 2025, where 45,000 shares were bought at an average price of €61.3667, totaling €2,761,501.50 [2]. - The lowest purchase price during this period was €53.5652 for 5,079 shares on April 24, 2025 [2]. Group 2: Company Overview - BIC is a global leader in stationery, lighters, and shavers, with a commitment to delivering high-quality and affordable products for over 80 years [4]. - The company operates in over 160 countries and employs more than 13,000 team members, featuring a diverse portfolio of iconic brands [4]. - BIC is listed on Euronext Paris and is included in the SBF120 and CAC Mid 60 indexes, highlighting its significant presence in the market [4].

Financial Data and Key Metrics Changes - The company reported worldwide revenue of $1,036 million for Q1 2025, a 12% increase compared to $921 million in Q1 2024, with organic revenue growth of 14% [18] - U.S. revenue totaled $751 million, up 15% from $653 million in Q1 2024, driven by strong new customer demand [19] - International revenue grew 7% to $286 million, with organic growth of 12% [21] - Gross profit was $596.2 million, representing 57.5% of revenue, down from 61.8% in Q1 2024 [23] - Operating income was $143.1 million, or 13.8% of revenue, compared to $140.2 million in the same quarter of 2024 [24] - Adjusted EBITDA was $230.4 million, or 22.2% of revenue, compared to $220.9 million, or 24% of revenue in Q1 2024 [25] - Net income for Q1 was $127.7 million, or $0.32 per share [26] Business Line Data and Key Metrics Changes - The company experienced record levels of new customer demand, particularly from the Type 2 non-insulin using population [9][10] - The introduction of Stello, the first over-the-counter CGM, and broader access in the Type 2 market contributed to increased customer starts [10][12] - The company launched a 180-day data look-back feature for the Stello app, enhancing customer experience [13] Market Data and Key Metrics Changes - The company secured access at two of the three largest PBMs for diabetes patients, which is expected to cover nearly six million people with Type 2 diabetes by the end of the year [10][11] - International business showed strength in Japan and France, with continued growth in the Type 2 landscape [22] Company Strategy and Development Direction - The company is focused on expanding coverage for Type 2 diabetes patients and enhancing customer experience through technology and software updates [10][12] - The introduction of the 15-day G7 system is expected to set a new industry standard for sensor accuracy and wear time [16] - The company is committed to addressing FDA concerns following a warning letter and is working on corrective actions [15][102] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply dynamics and maintaining customer care during the transition period [6][19] - The company reaffirmed its revenue guidance of $4.6 billion for the year, representing 14% growth, while adjusting gross margin guidance to approximately 62% [27][29] - Management is optimistic about the potential for broader Type 2 coverage and the positive reception of CGM technology in the healthcare landscape [10][110] Other Important Information - The company announced a $750 million share repurchase program, reflecting strong cash flow and financial position [26] - Management highlighted the importance of evidence-based data in driving changes to standards of care and expanding access globally [11] Q&A Session Summary Question: Did supply have any impact on the revenue growth? - Management indicated that supply dynamics were normalized by the end of the quarter, and strong new patient performance was observed despite previous challenges [35] Question: Why is full-year guidance unchanged despite strong Q1 growth? - Management stated that it is prudent to wait and see how the year unfolds before adjusting guidance, emphasizing the importance of a full-year perspective [42] Question: What are the trends in Type 2 patient utilization and reorder rates? - Management reported good retention and utilization rates among Type 2 patients, particularly those with reimbursement coverage [50] Question: How exposed is the company to a potential recession? - Management believes the company is well-positioned to weather economic downturns due to the cost-saving benefits of its products [58][60] Question: What is the status of the FDA warning letter? - Management confirmed that the warning letter does not restrict new submissions or approvals and that they are making progress in addressing FDA concerns [102] Question: What is the timeline for the RCT data readout for Type 2 non-insulin users? - Management anticipates finishing enrollment in the first half of the year, with initial data readout expected late this year or early next year [112]